VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Ending Cash Position : $0.81 Mil (As of Jun. 2008)

View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals Ending Cash Position?

VioQuest Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2008 was $0.81 Mil.

VioQuest Pharmaceuticals's quarterly Ending Cash Position declined from Dec. 2007 ($0.70 Mil) to Mar. 2008 ($0.31 Mil) but then increased from Mar. 2008 ($0.31 Mil) to Jun. 2008 ($0.81 Mil).

VioQuest Pharmaceuticals's annual Ending Cash Position declined from Dec. 2005 ($6.02 Mil) to Dec. 2006 ($2.93 Mil) and declined from Dec. 2006 ($2.93 Mil) to Dec. 2007 ($0.70 Mil).

VioQuest Pharmaceuticals Ending Cash Position Historical Data

The historical data trend for VioQuest Pharmaceuticals's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals Ending Cash Position Chart

VioQuest Pharmaceuticals Annual Data

Trend

Dec98

Dec99

Dec00

Dec01

Dec02

Dec03

Dec04

Dec05

Dec06

Dec07

Ending Cash Position

Get a 7-Day Free Trial

0.66

3.07

6.02

2.93

0.70

VioQuest Pharmaceuticals Quarterly Data
	Sep03	Dec03	Mar04	Jun04	Sep04	Dec04	Mar05	Jun05	Sep05	Dec05	Mar06	Jun06	Sep06	Dec06	Mar07	Jun07	Sep07	Dec07	Mar08	Jun08
Ending Cash Position	Get a 7-Day Free Trial															2.83	2.46	0.70	0.31	0.81

VioQuest Pharmaceuticals Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

VioQuest Pharmaceuticals's Ending Cash Position for the fiscal year that ended in Dec. 2007 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.932	+	-2.237
	=	0.70

VioQuest Pharmaceuticals's Ending Cash Position for the quarter that ended in Jun. 2008 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0.306	+	0.508
	=	0.81

VioQuest Pharmaceuticals Ending Cash Position Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 2287, Minneapolis, MN, USA, 55402

Website

VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.

Executives

Mark D Dacko	director, officer: CFO and Secretary	800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker	officer: V.P. & Chief Financial Officer	29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz	officer: CFO and Treasurer	65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam	director
Michael Weiser	director	C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli	director, officer: Secretary	C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf	director, officer: President and CEO	C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz	10 percent owner	WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen	director	TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines